Solubilization of Fluasterone in cosolvent/cyclodextrin combinations

Yan He, Ping Li, Samuel H Yalkowsky

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The combined effect of cosolvent (methanol (MeOH), ethanol (EtOH), or n-propanol (n-PrOH)) and complexant hydroxypropyl-β-cyclodextrin (HPβCD) on the solubility of Fluasterone is evaluated and explained with a simple equation. The calculated constants in the equation not only quantitatively describe the dependence of drug solubility on cosolvent and ligand concentrations, but also explain the minima that are observed in the Fluasterone solubility versus cosolvent concentration curves at fixed HPβCD concentrations.

Original languageEnglish (US)
Pages (from-to)25-34
Number of pages10
JournalInternational Journal of Pharmaceutics
Volume264
Issue number1-2
DOIs
StatePublished - Oct 2 2003

Fingerprint

Cyclodextrins
Solubility
1-Propanol
Substance-Related Disorders
Methanol
Ethanol
Ligands
5-androstene-16-fluoro-17-one

Keywords

  • Complexation
  • Cosolvent
  • Cyclodextrin
  • Fluasterone
  • Mixed solvent
  • Solubilization

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Solubilization of Fluasterone in cosolvent/cyclodextrin combinations. / He, Yan; Li, Ping; Yalkowsky, Samuel H.

In: International Journal of Pharmaceutics, Vol. 264, No. 1-2, 02.10.2003, p. 25-34.

Research output: Contribution to journalArticle

@article{4bf06cc5330649a4a38104e1f470c111,
title = "Solubilization of Fluasterone in cosolvent/cyclodextrin combinations",
abstract = "The combined effect of cosolvent (methanol (MeOH), ethanol (EtOH), or n-propanol (n-PrOH)) and complexant hydroxypropyl-β-cyclodextrin (HPβCD) on the solubility of Fluasterone is evaluated and explained with a simple equation. The calculated constants in the equation not only quantitatively describe the dependence of drug solubility on cosolvent and ligand concentrations, but also explain the minima that are observed in the Fluasterone solubility versus cosolvent concentration curves at fixed HPβCD concentrations.",
keywords = "Complexation, Cosolvent, Cyclodextrin, Fluasterone, Mixed solvent, Solubilization",
author = "Yan He and Ping Li and Yalkowsky, {Samuel H}",
year = "2003",
month = "10",
day = "2",
doi = "10.1016/S0378-5173(03)00389-2",
language = "English (US)",
volume = "264",
pages = "25--34",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Solubilization of Fluasterone in cosolvent/cyclodextrin combinations

AU - He, Yan

AU - Li, Ping

AU - Yalkowsky, Samuel H

PY - 2003/10/2

Y1 - 2003/10/2

N2 - The combined effect of cosolvent (methanol (MeOH), ethanol (EtOH), or n-propanol (n-PrOH)) and complexant hydroxypropyl-β-cyclodextrin (HPβCD) on the solubility of Fluasterone is evaluated and explained with a simple equation. The calculated constants in the equation not only quantitatively describe the dependence of drug solubility on cosolvent and ligand concentrations, but also explain the minima that are observed in the Fluasterone solubility versus cosolvent concentration curves at fixed HPβCD concentrations.

AB - The combined effect of cosolvent (methanol (MeOH), ethanol (EtOH), or n-propanol (n-PrOH)) and complexant hydroxypropyl-β-cyclodextrin (HPβCD) on the solubility of Fluasterone is evaluated and explained with a simple equation. The calculated constants in the equation not only quantitatively describe the dependence of drug solubility on cosolvent and ligand concentrations, but also explain the minima that are observed in the Fluasterone solubility versus cosolvent concentration curves at fixed HPβCD concentrations.

KW - Complexation

KW - Cosolvent

KW - Cyclodextrin

KW - Fluasterone

KW - Mixed solvent

KW - Solubilization

UR - http://www.scopus.com/inward/record.url?scp=0142028207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142028207&partnerID=8YFLogxK

U2 - 10.1016/S0378-5173(03)00389-2

DO - 10.1016/S0378-5173(03)00389-2

M3 - Article

VL - 264

SP - 25

EP - 34

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -